Fate Therapeutics Revenue and Competitors

Claim your profile

Location

$1.2B

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Fate Therapeutics's estimated annual revenue is currently $131.1M per year.(i)
  • Fate Therapeutics's estimated revenue per employee is $217,000
  • Fate Therapeutics's total funding is $1.2B.

Employee Data

  • Fate Therapeutics has 604 Employees.(i)
  • Fate Therapeutics grew their employee count by 53% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Fate Therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" iPS cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. The Company's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

keywords:N/A

$1.2B

Total Funding

604

Number of Employees

$131.1M

Revenue (est)

53%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Fate Therapeutics News

2022-04-17 - Fate Therapeutics, Inc. (NASDAQ:FATE) Insider Yu-Waye Chu Sells ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Insider Yu-Waye Chu Sells 4,062 Shares. Posted by admin on Apr 21st, 2022. Share on Twitter Share on Facebook Share on...

2022-04-17 - Fate Therapeutics to Webcast Conference Call Reporting First ...

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class...

2022-04-06 - Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Buy” by Brokerages. Posted by admin on Apr 11th, 2022.

2021-08-19 - Fate's close­ly watched stem cell-de­rived NK pro­gram rais­es red flag over dura­bil­i­ty of re­sponse

At the cut­ting edge of on­col­o­gy re­search, biotechs like Fate Ther­a­peu­tics are look­ing for ways to craft next-gen cell ther­a­pies with­out re­ly­ing on pa­tients’ own cells. An ear­ly peek at the com­pa­ny’s clin­i­cal da­ta looks promis­ing, but will iffy dura­bil­i­ty re­sults prove a ...

2012-09-05 - Maker of stem cell modulators brings in $9.2 million for blood cancer trials

Location: San Diego, California. Solution/product: Fate develops stem cell modulators. Its lead drug, ProHema, uses a small molecule (FT1050) to modulate hematopoietic stem cells (HSC), or blood-forming cells, that are transplanted to restore cells destroyed during intensive chemotherapy, radia ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$158.8M60511%N/A
#2
$160.1M61017%N/A
#3
$35M61117%N/A
#4
$15M61116%N/A
#5
$73.5M61979%$2B